Mark Brister Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Mark Brister.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Mark Brister. Mark Brister is VP Advanced Development Teams in DEXCOM INC ($DXCM) and Chief Technology Officer in OBALON THERAPEUTICS INC ($OBLN) and VP of Research and Development in OBALON THERAPEUTICS INC ($OBLN).
Latest Insider Trading Transactions of Mark Brister
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 28 2019 | OBLN | OBALON THERAPEUTIC ... | Brister Mark | Chief Technology Of ... | Option Exercise | A | 1.75 | 13,000 | 22,750 | 13,000 | |
| Oct 28 2019 | OBLN | OBALON THERAPEUTIC ... | Brister Mark | Chief Technology Of ... | Option Exercise | A | 1.75 | 13,000 | 22,750 | 13,000 | |
| Aug 08 2019 | OBLN | OBALON THERAPEUTIC ... | Brister Mark | Chief Technology Of ... | Option Exercise | P | 4.40 | 3,750 | 16,500 | 3,750 | |
| Aug 08 2019 | OBLN | OBALON THERAPEUTIC ... | Brister Mark | Chief Technology Of ... | Buy | P | 4.00 | 5,000 | 20,000 | 38,865 | 33.9 K to 38.9 K (+14.76 %) |
| Jul 25 2019 | OBLN | OBALON THERAPEUTIC ... | Brister Mark | Chief Technology Of ... | Option Exercise | A | 0.96 | 35,000 | 33,600 | 35,000 | |
| Jan 04 2019 | OBLN | OBALON THERAPEUTIC ... | Brister Mark | Chief Technology Of ... | Option Exercise | A | 2.30 | 100,000 | 230,000 | 100,000 | |
| Aug 27 2018 | OBLN | OBALON THERAPEUTIC ... | Brister Mark | Chief Technology Of ... | Grant | A | 1.82 | 107,142 | 194,998 | 338,634 | 231.5 K to 338.6 K (+46.28 %) |
| Aug 27 2018 | OBLN | OBALON THERAPEUTIC ... | Brister Mark | Chief Technology Of ... | Grant | A | 1.82 | 107,142 | 194,998 | 338,634 | 231.5 K to 338.6 K (+46.28 %) |
| May 02 2018 | OBLN | OBALON THERAPEUTIC ... | Brister Mark | Chief Technology Of ... | Grant | A | 3.27 | 2,622 | 8,574 | 166,492 | 163.9 K to 166.5 K (+1.60 %) |
| Jan 04 2018 | OBLN | OBALON THERAPEUTIC ... | Brister Mark | Chief Technology Of ... | Grant | A | 0.00 | 65,000 | 0 | 65,000 | 0 to 65 K |
| Nov 02 2017 | OBLN | OBALON THERAPEUTIC ... | Brister Mark | Chief Technology Of ... | Grant | A | 7.17 | 1,860 | 13,336 | 163,870 | 162 K to 163.9 K (+1.15 %) |
| May 02 2017 | OBLN | OBALON THERAPEUTIC ... | Brister Mark | VP of Research and ... | Grant | A | 9.03 | 1,550 | 13,997 | 162,010 | 160.5 K to 162 K (+0.97 %) |
| Nov 14 2016 | OBLN | OBALON THERAPEUTIC ... | Brister Mark | VP of Research and ... | Option Exercise | A | 8.74 | 90,000 | 786,600 | 90,000 | |
| May 04 2006 | DXCM | DEXCOM INC | Brister Mark | VP Advanced Develop ... | Sell | S | 24.00 | 50,000 | 1,200,000 | 10,967 | 61 K to 11 K (-82.01 %) |
Page: 1